MRD in AML: Time for redefinition of CR?

Blood

Volumn 121, Issue 12, 2013, Pages 2166-2168

  Ossenkoppele, Gert ^a   Schuurhuis, Gerrit Jan ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CBFB PROTEIN; CD135 ANTIGEN; CORE BINDING FACTOR; K RAS PROTEIN; KIT PROTEIN; MYH11 PROTEIN; N RAS PROTEIN; PROTEIN; RUNX1T1 PROTEIN; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE MYELOID LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CHROMOSOME ABERRATION; DISEASE FREE SURVIVAL; GENE MUTATION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; ACUTE GRANULOCYTIC LEUKEMIA; FEMALE; GENETICS; MALE; MUTATION; NOTE; PATHOLOGY; TUMOR GENE;

CORE BINDING FACTORS; FEMALE; GENES, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION;

MLCS; MLOWN;

EID: 84877930147     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-480590     Document Type: Review

References (6)

1. Jourdan E, Boissel N, Chevret S, et al, for the French AML Intergroup. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013; 121(12):2213-2223.
2. Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
3. Yin JA, O'Brien MA, Hills RK, et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: Results of the United Kingdom MRC AML-15 trial. Blood. 2012;120(14): 2826-2835.
4. Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: An integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9(10):579-590.
5. Krönke J, Schlenk RF, Jensen KO, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: A study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol. 2011;29(19): 2709-2716.
6. Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, Ho PA, Franklin J, Cooper TM, Gamis AS, Meshinchi S. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: A report from Children's Oncology Group. Blood. 2012;120(8):1581-1588.